Pharmaceutical Batch Records
cGMP batch records with in-process controls, deviations, and release testing -- the pharma data FDA 483s are made of.
No listings currently in the marketplace for Pharmaceutical Batch Records.
Find Me This Data →Overview
What Is Pharmaceutical Batch Records?
Pharmaceutical batch records are comprehensive manufacturing documents that capture every step of drug production under cGMP regulations. They include in-process controls, deviations, release testing results, and quality documentation that form the foundation of FDA compliance and regulatory inspections. These records serve as the critical link between product quality, regulatory oversight, and patient safety—whether maintained as paper documents or digitized through electronic batch record (EBR) systems. For virtual pharmaceutical manufacturers and CDMOs, batch records represent the single most important document connecting outsourced manufacturing operations to corporate compliance and quality assurance.
Market Data
USD 28 billion
Global EBR Market Size (2025)
Source: Future Market Insights
USD 85 billion
Projected Market (2035)
Source: Future Market Insights
12% CAGR (2025–2035)
Market Growth Rate
Source: Future Market Insights
67% of EBR adoption
Pharma & Biotech Market Share (2024)
Source: Towards Healthcare
~50% linked to human error
FDA Quality Issues from Manual Handling
Source: BizData360 / FDA
Who Uses This Data
What AI models do with it.do with it.
Pharmaceutical Manufacturers
Large and mid-sized pharma companies use batch records to document cGMP compliance, manage deviations, and prepare defensible documentation for FDA inspections and 483 observations.
Virtual Pharmaceutical Companies
Asset-light biotech firms and virtual manufacturers rely on batch records from CDMOs to maintain regulatory oversight, ensure product quality, and accelerate batch release decisions without owning manufacturing facilities.
Contract Manufacturing Organizations (CDMOs)
CDMOs generate and maintain batch records for sponsored products, capturing in-process controls, process deviations, and testing data required for client compliance and regulatory submissions.
Quality Assurance & Regulatory Affairs
QA teams, regulatory specialists, and compliance officers review batch records to detect deviations, assess product release readiness, and prepare for audits and regulatory inspections.
What Can You Earn?
What it's worth.worth.
Paper Batch Records (Manual Processing)
Varies
Digitization and review services command variable fees based on batch volume, complexity, and ALCOA+ compliance requirements. Virtual pharma companies often outsource scanning and data extraction.
Electronic Batch Record (EBR) Software Licensing
Pricing varies based on volume, exclusivity, and licensing terms
Note: Market research reports about this category typically run several thousand dollars, but actual data licensing prices are negotiated case-by-case based on volume, freshness, and exclusivity.
AI-Powered Batch Review & Analytics
Varies
Automated deviation detection, AI-integrated batch review, and data analytics services command premium pricing as adoption of ML and automation increases compliance speed and reduces error rates.
What Buyers Expect
What makes it valuable.valuable.
ALCOA+ Compliance
Records must meet Attributability, Legibility, Contemporaneousness, Originality, Accuracy, and Plus principles—especially critical for virtual pharma sponsors managing outsourced manufacturing and defending batch release decisions.
Data Integrity & Auditability
Buyers require complete traceability of deviations, control results, and quality decisions with electronic signatures, change logs, and audit trails for FDA 483 defense and regulatory inspections.
Deviation & Exception Handling
Clear documentation of in-process deviations, investigations, and corrective actions is essential. Systems must automatically flag anomalies and enable rapid root-cause analysis and decision-making.
Interoperability & Integration
Records must integrate seamlessly with quality management systems, analytics platforms, and MES/ERP infrastructure to enable data-driven quality, faster batch release, and reduced manual documentation error.
Companies Active Here
Who's buying.buying.
Manufacturing execution systems (MES) and batch record integration for pharma production environments.
Enterprise resource planning and quality compliance platforms supporting batch record management across large pharma and biotech operations.
Quality intelligence and batch record software platform serving pharmaceutical manufacturers and CDMOs.
Document management and batch record systems for quality compliance and regulatory documentation in pharmaceuticals.
Electronic batch record systems and manufacturing intelligence solutions for pharma and life sciences.
FAQ
Common questions.questions.
Why are paper batch records becoming a compliance risk for virtual pharmaceutical manufacturers?
Virtual manufacturers outsource production to CDMOs and typically receive hundreds or thousands of scanned paper pages per batch weeks after manufacturing. This creates delayed visibility, high documentation error rates, and limited data usability for compliance and batch release decisions. Paper records increase ALCOA+ risk and slow regulatory approval.
What percentage of FDA quality issues are linked to batch record errors?
Approximately 50% of pharmaceutical product quality issues are linked to human error during manual batch record handling and review, according to FDA data. This underscores the critical need for automated batch review and digitization.
Which segment is driving fastest growth in batch record adoption?
The analytics and reporting segment is experiencing the fastest growth, driven by AI and machine learning integration. These technologies enable automated batch reviews, data-driven decision-making, and rapid deviation detection—capabilities increasingly expected by regulators and quality teams.
What is the projected size of the electronic batch records market by 2035?
The global electronic batch records market is projected to reach USD 85 billion by 2035, growing at a 12% CAGR from 2025. This reflects accelerating adoption of cloud-based systems, AI automation, and digitization across pharma, biotech, CDMOs, and medical device manufacturers.
Sell yourpharmaceutical batch recordsdata.
If your company generates pharmaceutical batch records, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation